Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid. » Read More
For doctors and nurses in a growing number of hospitals, worrying about security when they input data into computers requires a balancing act.
Perrigo plummeted 13 percent in the premarket Monday after issuing very weak guidance.
Shares of Sarepta Therapeutics plunge after the FDA maintains its "negative" outlook on the company's drug for a rare muscle-wasting disorder.
Novartis is discussing options with banks for selling its $13.8 billion stake in rival Roche, though a sale is not imminent.
Dick Kovacevich defended the embattled lab testing start-up's boss, Elizabeth Holmes, saying her treatment recently has been unfair.
The broader U.S. stock market has only seen slight gains this year, but shares of GW Pharmaceuticals are flying high in 2016.
When it comes to the explosion of opioid abuse in the U.S., large employers are footing a big chunk of the bill.
If you signed up for a UnitedHealth Group plan on an Obamacare exchange for 2016, don't count on renewing your coverage next year if you live in Connecticut, Michigan, or dozens of other states.
UnitedHealth reported a 14 percent rise in profit helped by strength in its Optum business which offers health care services and drug benefit plans.
Johnson & Johnson also saw earnings beating and revenue matching estimates. The health-care giant also raised its yearly outlook.
Federal regulators are investigating blood-testing start-up Theranos over whether it misled investors.
There should be no continental U.S. travel restrictions for pregnant women due to Zika concern, NIH's Dr. Anthony Fauci tells CNBC.
AstraZeneca has held internal talks about a bid for cancer treatment maker Medivation but has yet to make a formal offer, the Sunday Times reported.
CEO Elizabeth Holmes says Theranos is rebuilding its laboratory from scratch "so that we can ensure it never happens again."
UnitedHealth's earnings set the tone for the health sector, and this quarterly report may be even more of a bellwether than usual.
Bill Miller said the troubled pharmaceutical company should be worth about double its current trading price.
Get the best of CNBC in your inbox